Literature DB >> 7909989

Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia.

R Mant1, J Williams, P Asherson, E Parfitt, P McGuffin, M J Owen.   

Abstract

We have reported an association between schizophrenia and homozygosity of a Bal I polymorphism in the first exon of the dopamine D3 receptor gene (Crocq et al.: Journal of Medical Genetics 29:858-860, 1992). The present study consists of an attempt to replicate this finding in a further sample of 66 patients and 97 controls. Once again more patients than controls were homozygous, but the effect was not as strong as in our first study (chi 2 = 2.53, P = 0.05, one tailed). When pooled data from our two studies were analysed, excess homozygosity in patients remained highly significant (P = 0.002) with a particular excess of the 1:1 genotype (P = 0.01). This reflected a departure from Hardy-Weinberg equilibrium in the patients (P = 0.0005) but not the controls (P = 0.24). This led us to explore the possibility that there might be important differences between the patients in our two studies and that excess homozygosity might be a characteristic of particular subgroups of schizophrenics. Our findings suggest that the effect is consistently at its strongest in those patients who have a high familial loading and in those who have a good response to neuroleptic treatment, and that differences between our two samples might have contributed to the quantitatively different outcomes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909989     DOI: 10.1002/ajmg.1320540106

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  11 in total

Review 1.  Genetic analyses of schizophrenia.

Authors:  C N Pato; K M Schindler; M T Pato
Journal:  Curr Psychiatry Rep       Date:  2000-04       Impact factor: 5.285

Review 2.  Molecular genetics of schizophrenia: a critical review.

Authors:  Neeraj Berry; Vaidehi Jobanputra; Hemraj Pal
Journal:  J Psychiatry Neurosci       Date:  2003-11       Impact factor: 6.186

3.  Prefrontal executive function and D1, D3, 5-HT2A and 5-HT6 receptor gene variations in healthy adults.

Authors:  Hsien-Yuan Lane; Yi-Ching Liu; Chieh-Liang Huang; Ching-Liang Hsieh; Yi-Lin Chang; Lauren Chang; Yue-Cune Chang; Wen-Ho Chang
Journal:  J Psychiatry Neurosci       Date:  2008-01       Impact factor: 6.186

4.  A search for association between schizophrenia and dopamine-related alleles.

Authors:  E Jönsson; S Brené; T Geijer; L Terenius; A Tylec; M L Persson; G Sedvall
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

Review 5.  The role of candidate genes in the etiology of schizophrenia.

Authors:  K C Murphy; P McGuffin
Journal:  Mol Med       Date:  1996-11       Impact factor: 6.354

6.  Selective expression of dopamine D3 receptor mRNA in proliferative zones during embryonic development of the rat brain.

Authors:  J Diaz; S Ridray; V Mignon; N Griffon; J C Schwartz; P Sokoloff
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

7.  Enhanced cleavage of an atypical intron of dopamine D3-receptor pre-mRNA in chronic schizophrenia.

Authors:  C Schmauss
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

Review 8.  Molecular genetics of schizophrenia: past, present and future.

Authors:  Suman Prasad; Prachi Semwal; Smita Deshpande; Triptish Bhatia; V L Nimgaonkar; B K Thelma
Journal:  J Biosci       Date:  2002-02       Impact factor: 1.826

9.  Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia.

Authors:  S Shaikh; D A Collier; P C Sham; D Ball; K Aitchison; H Vallada; I Smith; M Gill; R W Kerwin
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

10.  The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation.

Authors:  Lingjun Zuo; Xingguang Luo; John H Krystal; Joyce Cramer; Dennis S Charney; Joel Gelernter
Journal:  Pharmacogenet Genomics       Date:  2009-06       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.